Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: Preliminary results

Leukemia and Lymphoma

Volumn 53, Issue 3, 2012, Pages 499-502

  Anderlini, Paolo ^a   Saliba, Rima M ^a   Ledesma, Celina ^a   Chancoco, Christina ^a   Alousi, Amin M ^a   Shpall, Elizabeth J ^a   Popat, Uday R ^a   Hosing, Chitra M ^a   Khouri, Issa F ^a   Nieto, Yago ^a   Ciurea, Stefan ^a   Younes, Anas ^a   Fanale, Michelle A ^a   Acholonu, Sandra ^a   Valverde, Rosamar ^a   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; GEMCITABINE; MELPHALAN; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CHIMERA; COUGHING; DRUG DOSE REGIMEN; DYSPNEA; ENGRAFTMENT; ESOPHAGITIS; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART ATRIUM FIBRILLATION; HODGKIN DISEASE; HUMAN; HYPERTENSION; LETTER; LUNG TOXICITY; MUCOSA INFLAMMATION; NEUTROPHIL COUNT; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REDUCED INTENSITY CONDITIONING; RESPIRATORY FAILURE; SKIN TOXICITY; STOMATITIS; TACHYCARDIA; VIRUS PNEUMONIA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HODGKIN DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELPHALAN; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 84857565259     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.615427     Document Type: Letter

References (15)

1. P eggs KS, Anderlini P, Sureda A. Allogeneic transplantation for Hodgkin lymphoma. Br. J. Haematol. 2008;143:468-480.
2. Robinson SP, Sureda A, Canals C., et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin lymphoma: Identifi cation of prognostic factors predicting outcome. Haematologica 2009;94:230-238.
3. P eggs KS, Hunter A, Chopra R., et al. Clinical evidence of a graft-versus-lymphoma eff ect after reduced-intensity allogeneic transplantation. Lancet 2005;365:1906-1908.
4. A nderlini P, Saliba R, Acholonu S., et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkins lymphoma: The updated M.D. Anderson Cancer Center experience. Haematologica 2008;93:257-64. (Pubitemid 351397714)
5. Oki Y, Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma 2008;49:883-889. (Pubitemid 351942740)
6. S antoro A, Bredenfi eld H, Devizzi L., et al. Gemcitabine in the treatment of refractory Hodgkins disease: Results of a multicenter phase II study. J. Clin. Oncol. 2000;18:2615-2619. (Pubitemid 30432529)
7. Friedberg JW, Neuberg D, Kim H., et al. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer 2003;98:978-982. (Pubitemid 37022098)
8. Straus DJ, Johnson JL, LaCasce AS., et al. Doxorubicin, vinblastine and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: Pretreatment prognostic factors and interim PET. Blood 2011;117:5314-5320.
9. Arai S, Letsinger R, Wong RM., et al. Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2010;16:1145-1154.
10. Kanda Y, Omuro Y, Baba E., et al. Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: A Japanese survey. Bone Marrow Transplant 2008;42:99-103.
11. Shanks RH, Rizzieri DA, Flowers JL., et al. Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. Clin. Cancer Res.. 2005;11:4225-4233. (Pubitemid 40791589)
12. K aplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
13. De Lima M, Anagnostopoulos A, Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004;104:865-872. (Pubitemid 38970586)
14. R izzieri DA, Ibom VK, Moore JO., et al. Phase I evaluation of prolonged-infusion gemcitabine with fl udarabine for relapsed or refractory acute myelogenous leukemia. Clin. Cancer Res.. 2003;9:663-668. (Pubitemid 36182598)
15. Gandhi V. Questions about gemcitabine dose rate: Answered or unanswered? J. Clin. Oncol. 2007;25:5691-5694.